Sanovel Pharmaceuticals

Sanovel, a 100% Turkish capitalized company, operates in the pharmaceutical industry for over 30 years, and has created a distinguished name for having a dynamic and innovative structure. Sanovel has 2500 employees with having one of the largest sales&marketing team in Turkey. As of 2016, the company has growth 3 times higher than the total market also by adding a considerable number of first to market generics to its portfolio for 2017. Closely following the developments in the world, Sanovel is the leading company in Turkey on investing and developing value-added branded generics, high technology products and also device included respiratory products. As a result of these investments, Sanovel accomplished to be the first Turkish firm to ever have an approved patent from the American Patent Office. Sanovel has earned the right to preserve the American patents of the four medical formulations until 2033.Sanovel has an EU GMP approved facility with a 60.000 sqm and capable of manufacturing all pharmaceutical dosage forms. Sanovel has 148 branded generics in its portfolio and exists in both local and international markets with this large portfolio. Export operations have started in 2005 and are ongoing with significant growth each year. Spain, Russia, Ukraine, CIS, Balkan States, LATAM, South Asia, South Africa, MENA and Europe are some of the regions that Sanovel has either strong partnerships or its own sales & marketing teams.Sanovel Pharmaceutical’s manufacturing site located in Silivri/Çatalköy has received approval from the USA Food and Drug Administration – FDA in September 2018. Sanovel Pharmaceutical has become the first and only Turkish pharmaceutical company to receive FDA approval without any major or critical finding. Having successfully passed the FDA Audit, Sanovel Pharmaceutical is continuing its efforts towards exporting its products to the US market at full force. As a result, the company is about to receive approval for the authorization application it made last year.